SphereBio develops a biotech delivery platform that utilizes synthetic virology and nanotechnology to train immune cells to recognize and attack cancer cells based on the unique identity of each tumor. This personalized approach aims to enhance treatment efficacy while minimizing side effects, addressing the limitations of current cancer therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer therapies often fail to provide effective and lasting treatment, resulting in millions of deaths annually. Existing treatments may lack precision, leading to significant side effects and limited efficacy due to the unique characteristics of each patient's tumor.
Solution
SphereBio is developing a biotech delivery platform that leverages synthetic virology and nanotechnology to create personalized cancer vaccines. The platform trains immune cells to recognize and attack cancer cells based on the unique identity of each tumor. By decoding each tumor using bioinformatics algorithms, SphereBio identifies patterns and designs tailored therapies for individual patients. This approach aims to enhance treatment efficacy while minimizing side effects, offering pharmaceutical companies a novel method for creating patient-specific treatment alternatives.
Target Audience
SphereBio's primary customers are pharmaceutical companies seeking innovative approaches to develop personalized cancer therapies.
Features
- Bioinformatics algorithms to decode tumor-specific characteristics and identify therapeutic targets.
- Synthetic virology combined with nanotechnology for efficient delivery of therapeutic molecules to cells.
- Personalized cancer vaccines tailored to each patient's unique tumor profile.
- Technology to train immune cells to specifically recognize and eliminate cancer cells.